Lyndsay V Rhodes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1279413/publications.pdf

Version: 2024-02-01

46 papers

2,142 citations

236833 25 h-index 289141 40 g-index

47 all docs

47 docs citations

47 times ranked

3818 citing authors

#	Article	IF	CITATIONS
1	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Research, 2012, 14, R79.	2.2	213
2	Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Research, 2015, 17, 112.	2.2	152
3	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. Cancer Research, 2011, 71, 603-613.	0.4	140
4	Endocrine Disruptor Regulation of MicroRNA Expression in Breast Carcinoma Cells. PLoS ONE, 2012, 7, e32754.	1.1	128
5	Antiestrogenic Effects of the Novel Sphingosine Kinase-2 Inhibitor ABC294640. Endocrinology, 2010, 151, 5124-5135.	1.4	105
6	Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment, 2010, 121, 293-300.	1.1	101
7	Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Research, 2013, 15, R102.	2.2	99
8	Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Research, 2012, 14, R45.	2.2	95
9	Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Molecular Cancer, 2010, 9, 295.	7.9	89
10	Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget, 2015, 6, 16638-16652.	0.8	86
11	Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Research and Treatment, 2014, 145, 593-604.	1.1	85
12	Glyceollin I, a Novel Antiestrogenic Phytoalexin Isolated from Activated Soy. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 35-45.	1.3	71
13	A new method for stranded whole transcriptome RNA-seq. Methods, 2013, 63, 126-134.	1.9	59
14	The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports, 2012, 27, 10-6.	1.2	58
15	Human Uterine Smooth Muscle and Leiomyoma Cells Differ in Their Rapid 17β-Estradiol Signaling: Implications for Proliferation. Endocrinology, 2009, 150, 2436-2445.	1.4	51
16	MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis. PLoS ONE, 2013, 8, e69291.	1.1	50
17	Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. Oncology Letters, 2012, 3, 163-171.	0.8	48
18	Effects of 7-O Substitutions on Estrogenic and Anti-Estrogenic Activities of Daidzein Analogues in MCF-7 Breast Cancer Cells. Journal of Medicinal Chemistry, 2010, 53, 6153-6163.	2.9	47

#	Article	IF	CITATIONS
19	Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. Journal of Molecular Endocrinology, 2011, 46, 205-216.	1.1	47
20	Preferential star strand biogenesis of preâ€miRâ€24â€2 targets PKCâ€alpha and suppresses cell survival in MCFâ€7 breast cancer cells. Molecular Carcinogenesis, 2014, 53, 38-48.	1.3	45
21	Elevated expression of long intergenic nonâ€coding RNA HOTAIR in a basalâ€like variant of MCFâ€7 breast cancer cells. Molecular Carcinogenesis, 2015, 54, 1656-1667.	1.3	35
22	Effects of SDF-1–CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Experimental Cell Research, 2011, 317, 2573-2581.	1.2	32
23	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. Scientific Reports, 2012, 2, 539.	1.6	32
24	Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology, 2013, 42, 1139-1150.	1.4	32
25	Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis, 2015, 4, e168-e168.	2.1	30
26	Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events. Journal of Cell Science, 2010, 123, 401-412.	1.2	26
27	microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Molecular Cancer, 2014, 13, 229.	7.9	26
28	Phytoalexins, miRNAs and Breast Cancer: A Review of Phytochemical-mediated miRNA Regulation in Breast Cancer. Journal of Health Care for the Poor and Underserved, 2013, 24, 36-46.	0.4	24
29	Insulin-Like Growth Factor-1 Signaling Regulates miRNA Expression in MCF-7 Breast Cancer Cell Line. PLoS ONE, 2012, 7, e49067.	1.1	22
30	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 169, 381-390.	1.1	19
31	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. BMC Cancer, 2019, 19, 205.	1.1	19
32	Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2015, 150, 17-23.	1.2	18
33	Resveratrol analogues surprisingly effective against tripleâ€'negative breast cancer, independent of ERα. Oncology Reports, 2019, 41, 3517-3526.	1.2	16
34	Glyceollin-Elicited Soy Protein Consumption Induces Distinct Transcriptional Effects As Compared to Standard Soy Protein. Journal of Agricultural and Food Chemistry, 2012, 60, 81-86.	2.4	15
35	In Vitro and In Vivo evaluation of novel anticancer agents in triple negative Breast Cancer Models. Journal of Health Care for the Poor and Underserved, 2013, 24, 104-111.	0.4	11
36	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Non-coding RNA, 2016, 2, 8.	1.3	11

3

#	Article	lF	CITATIONS
37	Human Mesenchymal Stem Cells as Mediators of Breast Carcinoma Tumorigenesis and Progression. Scientific World Journal, The, 2010, 10, 1084-1087.	0.8	2
38	Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrantâ€'resistant phenotype in breast cancer cells. Oncology Letters, 2021, 21, 380.	0.8	1
39	Abstract 3318: Exploring the utility of natural and synthetic resveratrol derivatives for bone regrowth following loss due to breast cancer therapies. Cancer Research, 2016, 76, 3318-3318.	0.4	1
40	Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model., 2010 ,,.		0
41	Abstract A016: Electrical impedance assessment of the effect of LBH589 on the cellular behavior and migratory potential of breast cancer cells. , 2013, , .		O
42	Abstract 1052: Dual role of MEK1/2 and MEK5 in the reversal of epithelial-to-mesenchymal transition. , 2014, , .		0
43	Abstract 1034: ZEB2 promotes cell motility and metastasis in ER+ breast cancer cells., 2014,,.		O
44	Abstract 1571: The tumor suppressor Liver Kinase B1 inhibits triple-negative breast cancer cell metastasis via regulation of AP-1 signaling. , 2014, , .		0
45	Abstract 4410: ZEB2 drives cell motility and metastasis in ER+ breast cancer cells through a novel, E-cadherin independent pathway. , 2016, , .		O
46	Abstract 1596: Induction of mesenchymal-to-epithelial transition through pan-MEK inhibition in triple-negative breast cancer., 2016,,.		O